Marc Newell, MD
Cardiovascular Disease · Minneapolis, MNNPI 1467404707
Payments from drug & device makers
What this record shows
Medtronic accounts for 93.3% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $1,579 and has fallen 72.0% since, to $442 in 2024.
Across 23 payments — averaging $107.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Heartflow, Inc.$166
Across 7 payments — averaging $10,346 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$40K
- Boehringer Ingelheim Pharma GmbH & Co.kg$33K
Across 1 payment — averaging $53,300 each. An ownership or investment interest held by the physician or an immediate family member.
- Nascent Surgical LLC$53K
What the payments were for
- Travel & lodging$1,20448%
- Food & beverage$1,28052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 21 | $2,317 |
| Heartflow, Inc. | 2 | $166 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$162
How this compares
$2,483 in reported general payments places this provider in the 60th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 163 | $216,092 |
| XareltoRivaroxaban | 33 | $52,757 |
| Repatha SureclickEvolocumab | 40 | $44,725 |
| Metoprolol Succinate | 154 | $2,821 |
| Atorvastatin Calcium | 150 | $2,515 |
| Rosuvastatin Calcium | 161 | $2,457 |
| Carvedilol | 125 | $1,567 |
| Ezetimibe | 35 | $1,302 |
| Lisinopril | 79 | $990 |
| Losartan Potassium | 81 | $888 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 31 | $745 |
| ClopidogrelClopidogrel Bisulfate | 50 | $714 |
| Amlodipine Besylate | 74 | $608 |
| Furosemide | 49 | $522 |
| Metoprolol Tartrate | 63 | $519 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Minneapolis
- Jeffrey ChambersMinneapolis$3.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
- David HurrellMinneapolis$205K
- Yader Sandoval PichardoMinneapolis$157K
- Charles HerzogMinneapolis$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.